Sai Life Sciences Limited has released its sixth sustainability report for FY2024-25, demonstrating the company's commitment to responsible growth and environmental stewardship. The report, aligned with Global Reporting Initiative (GRI) Universal Standards 2021 and Sustainability Accounting Standards Board (SASB) standards, is presented under the theme "Driving climate action, deepening stakeholder trust."

Strategic Framework and Sustainability Pillars

The company's sustainability strategy is anchored in nine strategic pillars that collectively guide its approach to responsible growth. These comprehensive elements span multiple areas of operation and stakeholder engagement:

These elements constitute a cohesive framework that embeds sustainability priorities into every stage of the company's operations, aligning with business objectives and stakeholder expectations.

Key Performance Achievements

The report highlights significant progress across multiple sustainability metrics during FY2024-25. The company advanced its internally defined Sustainable Development Goals (SDGs), which outline a clear roadmap for meeting sustainability commitments by March 31, 2027.

Environmental Progress

Social Impact and Community Engagement

Sai Life Sciences demonstrated substantial community impact, surpassing its commitment to provide education and livelihood opportunities for 8,000 individuals from underprivileged communities. The organization also strengthened its people agenda with steady growth in diversity initiatives.

Leadership Perspective and Future Outlook

Krishna Kanumuri, MD & CEO of Sai Life Sciences, emphasized the company's commitment to reliability with responsibility as central to the CRDMO mandate. He highlighted the translation of this commitment into action through progress across climate actions, circular economy initiatives, people-led HR transformation, and tech-enabled innovation.

The company is focused on scaling these efforts to build a resilient, science-forward, and sustainability-led operating model that delivers enduring value to partners and stakeholders. The 2024-25 sustainability report reflects the company's long-term view that places science, responsibility, and collaboration at the center of its growth ambition.

Regulatory Compliance and Reporting

The sustainability report release was announced pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This sixth edition continues the company's commitment to transparent reporting and stakeholder communication regarding its sustainability initiatives and progress.

As Sai Life Sciences continues to expand its global footprint with operations across India, the UK, and the US, sustainability remains both a compass and a catalyst for shaping resilient, future-ready operations in the contract research, development, and manufacturing sector.

The report highlights the company's progress in climate action, increased renewable energy usage, and impactful community initiatives, aligning with its commitment to responsible growth and environmental stewardship.

Sai Life Sciences Limited , a prominent player in the pharmaceutical industry, is now facing a third significant tax demand from authorities, adding to its ongoing GST-related disputes. The latest development brings the company's total tax demands to over ₹80 crores across multiple cases.

Latest GST Demand Order

On December 10, 2025, Sai Life Sciences received a new GST demand order dated December 9, 2025, from the Deputy Commissioner of Commercial Taxes (Audit), Bidar. This latest order was passed under Section 73(9) of the Goods and Services Tax Act, 2017.

The demand pertains to alleged excess availment of Input Tax Credit in GSTR-3B compared to what was available in GSTR-2A for the financial year 2021-22.

Previous Karnataka Tax Authority Demand

Earlier, the Joint Commissioner of Commercial Taxes in Karnataka had issued an order demanding ₹36.68 crores from the company for alleged non-payment of taxes on intermediary services received from its US subsidiary.

This demand covered the period from July 2017 to March 2022, relating to services received from Sai Life Sciences Inc., USA, under the reverse charge mechanism.

Second GST Demand

In addition to these two major demands, Sai Life Sciences had previously received another GST demand order totaling ₹10.67 crores, including interest and penalties, for alleged excess Input Tax Credit availment and discrepancies in B2B supply records for fiscal year 2020-21.

Company's Response Strategy

Sai Life Sciences has consistently maintained its stance of appealing all GST demand orders. Regarding the latest demand, the company has stated that based on its assessment, an appeal will be filed. The company remains hopeful of a favorable outcome at the appellate level and does not reasonably expect the order to have any material financial impact.

This approach mirrors the company's response to previous demands, suggesting confidence in its tax compliance and documentation.

Cumulative Impact and Implications

With three separate GST demands now totaling over ₹80 crores, Sai Life Sciences faces significant regulatory scrutiny. However, the company's consistent position across all cases indicates a systematic approach to defending its tax positions.

For investors and stakeholders, these developments highlight the complex nature of GST compliance, particularly regarding Input Tax Credit claims and international transactions. The outcomes of these appeals could set important precedents for the pharmaceutical sector and companies with similar operational structures.